Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cemsidomide - C4 Therapeutics

Next Previous
Drug Profile

Cemsidomide - C4 Therapeutics

Alternative Names: CFT 7455

Latest Information Update: 07 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator C4 Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action IKZF1 protein degraders; IKZF3 protein degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 25 Mar 2026 C4 Therapeutics initiates a phase Ib trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) (PO)
  • 26 Feb 2026 C4 Therapeutics plans a phase Ib trial for Multiple myeloma (Combination therapy) in mid-2026
  • 31 Jan 2026 Phase-II clinical trials in Multiple myeloma (Second-line therapy or greater, Combination therapy) in USA (PO) (NCT07284758)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top